Corvus Pharmaceuticals Inc

A Stage 2 advancing context persists with a clear Lockout Rally driving forced participation above rising 9EMA, 20EMA, and 50DMA. Price is extended but the Lockout Rally override supports continued upside without typical exhaustion constraints. Medium- and short-term biases align bullish, presenting favorable conditions for Buy Now. Key risks include a deep pullback breaching EMA support and moderate transition risk toward Stage 3.

• ↑Phase I atopic dermatitis Cohort 3 yielded a 64.8% EASY score reduction vs. 40% placebo.
• ↑Raised $189 M via public offering; cash balance $56.8 M funds operations into 2026.
• ↓Q4 2025 R&D expenses rose to $9.9 M, driving net loss to $12.3 M.